FINNENCE ▪ THE WIRE FILE
THE WIRE · № 55475
Company▲ Bullish
New Phase 3 trial: A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity — Pfizer
KINDCompany
DIRECTION▲ Bullish
SOURCES1
ENTITIES2
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 12:00 UTC
LAST UPDATE2026-09-29 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Pfizer's Phase 3 obesity switch study pits berobenatide against semaglutide and tirzepatide, a competitive obesity-market signal.
Pfizer pushes into the obesity drug race
CATALYST TO WATCH
Trial enrollment and early efficacy data
MAIN RISK
Head-to-head against leaders is high risk
FULL DISPATCH
Sponsor: Pfizer; Status: Not Yet Recruiting; Conditions: Obesity, Overweight and/or Obesity, Overweight, Treatment Of Obesity; Interventions: Semaglutide, Tirzepatide, Berobenatide; Enrollment: 660 (estimated); First posted: 2026-09-29; NCT: NCT07845500
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDEli Lilly · LLY
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
New Phase 3 trial: A Study to Assess the Efficacy and Safety of Afimkibart for Induction Therapy in Participants With Moderately to Severely Active Ulcerative Colitis — Hoffmann-La Roche2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer — Seagen Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia — Otsuka Pharmaceutical Development & Commercialization, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare, LLY
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age — ModernaTX, Inc.2026-09-29 12:00 UTC
→CORRELATIONshares Healthcare
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
Another proposed mega merger: HealthPartners, Essentia Health boards approve plan to combine organizations2026-09-29 15:50 UTC
→CORRELATIONshares Healthcare
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.